OliX Pharmaceuticals to Participate in BIO-Europe Spring® | |
---|---|
Date : 2022-03-24 View : 1121 | |
OliX
Pharmaceuticals to Participate in BIO-Europe Spring® SUWON, South Korea -- OliX Pharmaceuticals, Inc.
(KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that
the Company’s management will participate in one-on-one partnering meetings at BIO-Europe
Spring. The event is being held digitally from March 28-31, 2022.
Dr. Sun Woo Hong, Head of External
Collaboration, and Dr. June Park, Principal Scientist, will meet industry
experts to discuss platform-based early discovery collaborations as well as global
licensing options for pipeline programs, including OLX101A for hypertrophic
scars (Phase 2), OLX703A for hepatitis B virus, and OLX702A for nonalcoholic
steatohepatitis.
This year, BIO-Europe Spring, Europe’s largest
springtime biopharma industry gathering, will serve the global biotechnology
industry, including more than 1000 companies from 45 countries. To schedule a
virtual meeting, please visit the BIO-Europe Spring® platform at https://informaconnect.com/bioeurope-spring/partnering/.
###
|
|
Prev | OliX Identifies Inhibition of Target Gene expression in Nonhuman Primate Models for NASH Candidate |
Next | OliX Pharmaceuticals Presents Potential Utility of GalNAc-asiRNA Platform at OPT Congress |
- Home
- PR